After raising $213 million in 2023—one of the year’s largest private biotech rounds—Tome Biosciences is making cuts.
Tome presented data updates on its programmable genomic integration technologies at ASGCT.
Tome to present data at ASGCT.
Tome granted US patent for programmable genomic integration.
Tome Biosciences Forms Science and Technology Advisory Committee
Tome Biosciences appoints Daniel Curran, MD, to its Board of Directors.
Genevant Sciences to Collaborate with Tome Biosciences
Tome acquires Replace Therapeutics.